Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Andrew C. Good
Observed names:
Andrew C Good,
Andrew Good,
Good, Andrew C.
Institutions:
Cambridge Intellectual Property (United Kingdom),
C4 Therapeutics (United States)
Observed institutions:
University of California, San Francisco,
GlaxoSmithKline (United Kingdom),
University of Oxford,
Bristol-Myers Squibb (United States),
Cambridge Intellectual Property (United Kingdom),
Constellation Pharmaceuticals (United States),
C4 Therapeutics (United States)
show all 7
ORCID:
0009-0001-9910-6475
Observed ORCID:
0009-0001-9910-6475
OpenAlex ID:
A5108812590
Molecular Shape and Medicinal Chemistry: A Perspective
2010
·
Anthony Nicholls
, Georgia B. McGaughey
, et al.
·
Journal of Medicinal Chemistry
·
329
PDF
Molecular docking towards drug discovery
1996
·
Daniel A. Gschwend
, Andrew C. Good
, et al.
·
Journal of Molecular Recognition
·
306
PDF
Identification of ( R )- N -((4-Methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1 H -indole-3-carboxamide (CPI-1205), a Potent and Selective Inhibitor of Histone Methyltransferase EZH2, Suitable for Phase I Clinical Trials for B-Cell Lymphomas
2016
·
Rishi G. Vaswani
, Victor S. Gehling
, et al.
·
Journal of Medicinal Chemistry
·
231
Optimization of CAMD techniques 3. Virtual screening enrichment studies: a help or hindrance in tool selection?
2008
·
Andrew C. Good
, Tudor I. Oprea
·
Journal of Computer-Aided Molecular Design
·
186
Structure-activity relationships from molecular similarity matrices
1993
·
Andrew C. Good
, Sung Sau So
, et al.
·
Journal of Medicinal Chemistry
·
162
Diving into the Water: Inducible Binding Conformations for BRD4, TAF1(2), BRD9, and CECR2 Bromodomains
2016
·
Terry D. Crawford
, Vickie Tsui
, et al.
·
Journal of Medicinal Chemistry
·
118
PDF
The Discovery of Asunaprevir (BMS-650032), An Orally Efficacious NS3 Protease Inhibitor for the Treatment of Hepatitis C Virus Infection
2014
·
Paul M. Scola
, Li-Qiang Sun
, et al.
·
Journal of Medicinal Chemistry
·
118
An Empirical Process for the Design of High-Throughput Screening Deck Filters
2006
·
Bradley C. Pearce
, Michael J. Sofia
, et al.
·
Journal of Chemical Information and Modeling
·
101
QSAR's from similarity matrices. Technique validation and application in the comparison of different similarity evaluation methods
1993
·
Andrew C. Good
, Stephen J. Peterson
, et al.
·
Journal of Medicinal Chemistry
·
93
Ranking poses in structure-based lead discovery and optimization: current trends in scoring function development.
2007
·
Ramkumar Rajamani
, Andrew C Good
·
PubMed
·
82
New Methodology for Profiling Combinatorial Libraries and Screening Sets: Cleaning Up the Design Process with HARPick
1997
·
Andrew C. Good
, Richard A. Lewis
·
Journal of Medicinal Chemistry
·
80
Discovery and Early Clinical Evaluation of BMS-605339, a Potent and Orally Efficacious Tripeptidic Acylsulfonamide NS3 Protease Inhibitor for the Treatment of Hepatitis C Virus Infection
2014
·
Paul M. Scola
, Alan Xiangdong Wang
, et al.
·
Journal of Medicinal Chemistry
·
76
Discovery, design, and synthesis of indole-based EZH2 inhibitors
2015
·
Victor S. Gehling
, Rishi G. Vaswani
, et al.
·
Bioorganic & Medicinal Chemistry Letters
·
68
The discovery of novel benzofuran-2-carboxylic acids as potent Pim-1 inhibitors
2011
·
Yibin Xiang
, Bradford Hirth
, et al.
·
Bioorganic & Medicinal Chemistry Letters
·
66
Measuring CAMD technique performance: A virtual screening case study in the design of validation experiments
2004
·
Andrew C. Good
, Mark A. Hermsmeier
, et al.
·
Journal of Computer-Aided Molecular Design
·
66
New molecular shape descriptors: Application in database screening
1995
·
Andrew C. Good
, Todd J. A. Ewing
, et al.
·
Journal of Computer-Aided Molecular Design
·
63
Bicyclic Helical Peptides as Dual Inhibitors Selective for Bcl2A1 and Mcl-1 Proteins
2018
·
Aline D. de Araujo
, Junxian Lim
, et al.
·
Journal of Medicinal Chemistry
·
61
Discovery of Rezatapopt (PC14586), a First-in-Class, Small-Molecule Reactivator of p53 Y220C Mutant in Development
2024
·
Binh T. Vu
, Romyr Dominique
, et al.
·
ACS Medicinal Chemistry Letters
·
58
Structural Characterization of Degrader-Induced Ternary Complexes Using Hydrogen–Deuterium Exchange Mass Spectrometry and Computational Modeling: Implications for Structure-Based Design
2021
·
Scott J. Eron
, Hongwei Huang
, et al.
·
ACS Chemical Biology
·
57
High-throughput and virtual screening: core lead discovery technologies move towards integration
2000
·
Andrew C. Good
, Stanley R. Krystek
, et al.
·
Drug Discovery Today
·
51
Three‐Dimensional Structure Database Searches
1996
·
Andrew C. Good
, Jonathan S. Mason
·
Reviews in computational chemistry
·
51
Acyl Guanidine Inhibitors of β-Secretase (BACE-1): Optimization of a Micromolar Hit to a Nanomolar Lead via Iterative Solid- and Solution-Phase Library Synthesis
2012
·
Samuel W. Gerritz
, Weixu Zhai
, et al.
·
Journal of Medicinal Chemistry
·
48
Analysis and optimization of structure-based virtual screening protocols
2003
·
Andrew C. Good
, Daniel L. Cheney
, et al.
·
Journal of Molecular Graphics and Modelling
·
47
Potent Inhibitors of Hepatitis C Virus NS3 Protease: Employment of a Difluoromethyl Group as a Hydrogen-Bond Donor
2018
·
Barbara Zheng
, Stanley V. D’Andrea
, et al.
·
ACS Medicinal Chemistry Letters
·
44
Abstract ND09: The discovery and characterization of CFT8634: A potent and selective degrader of BRD9 for the treatment of SMARCB1-perturbed cancers
2022
·
Katrina L. Jackson
, Roman V. Agafonov
, et al.
·
Cancer Research
·
40
Show more works
View as search
Works count:
79
Citation count:
3,312
H-index:
29
I10-index:
54
Year
Topic
Type